Playback speed
10 seconds
EHA 2024 Insights: Intrathecal Rituximab + Dex for Refractory Sanctuary CNS Involvement in B-Cell Malignancies
By
Insights from 2024 EHA Annual Meeting
FEATURING
Maher Salamoon
By
Insights from 2024 EHA Annual Meeting
FEATURING
Maher Salamoon
117 views
July 9, 2024
Chapters
Evaluating Venetoclax & Obinutuzumab for CLL
00:00
Weighing Time-Limited Therapy Against Continuous Therapy
02:40
Comments 0
Login to view comments.
Click here to Login
Recommended
AUTOPLAY